These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 1687102)
1. The over-expression of P-glycoprotein in K-562 and DAUDI cells, is associated with a high susceptibility to NK and LAK cells. Dupuis ML; Ramoni C; Yassen A; Samoggia P; Tombesi M; Caserta M; Cianfriglia M J Biol Regul Homeost Agents; 1991; 5(4):137-41. PubMed ID: 1687102 [TBL] [Abstract][Full Text] [Related]
2. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis. Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512 [TBL] [Abstract][Full Text] [Related]
3. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing. Wiebke EA; Custer MC; Rosenberg SA; Lotze MT J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373 [TBL] [Abstract][Full Text] [Related]
4. Susceptibility of multidrug-resistant human T-lymphoblastoid CEM cell line to cell-mediated cytolysis. Ramoni C; Dupuis ML; Cenciarelli C; Ciccolini F; Cianfriglia M Ann Ist Super Sanita; 1990; 26(3-4):433-9. PubMed ID: 1982604 [TBL] [Abstract][Full Text] [Related]
5. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation. Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943 [TBL] [Abstract][Full Text] [Related]
6. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines. Treichel RS; Olken S Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437 [TBL] [Abstract][Full Text] [Related]
7. Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinoma. Savas B; Kerr PE; Ustun H; Cole SP; Pross HF Anticancer Res; 1998; 18(6A):4355-61. PubMed ID: 9891492 [TBL] [Abstract][Full Text] [Related]
8. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells. Komatsu F; Kajiwara M Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151 [TBL] [Abstract][Full Text] [Related]
9. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity. Furbert-Harris PM; Evans CH Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871 [TBL] [Abstract][Full Text] [Related]
11. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy. Klasa RJ; Silver HK; Kong S Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154 [TBL] [Abstract][Full Text] [Related]
12. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition. Mueller EA; Anderer FA Cancer Res; 1990 Jun; 50(12):3646-51. PubMed ID: 1692765 [TBL] [Abstract][Full Text] [Related]
13. Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue. Donskov F; Basse PH; Hokland M Nat Immun; 1996-1997; 15(2-3):134-46. PubMed ID: 9162263 [TBL] [Abstract][Full Text] [Related]
14. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues. Colquhoun SD; Economou JS; Shau H; Golub SH J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167 [TBL] [Abstract][Full Text] [Related]
15. Antileukemia activity of a natural killer cell line against human leukemias. Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753 [TBL] [Abstract][Full Text] [Related]
16. [Human LAK cell induction and its biological characteristics]. Wu YY Zhonghua Zhong Liu Za Zhi; 1990 Jul; 12(4):254-7. PubMed ID: 2125554 [TBL] [Abstract][Full Text] [Related]
17. Decrease of lymphokine (interleukin-2)-activated killer activity in peripheral blood after administration of natural interferon-gamma. Yanagawa H; Sone S; Okubo A; Fukuta K; Nishioka Y; Ogura T Jpn J Clin Oncol; 1990 Dec; 20(4):356-63. PubMed ID: 2126575 [TBL] [Abstract][Full Text] [Related]
18. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells. Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774 [TBL] [Abstract][Full Text] [Related]
19. Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Kimmig A; Gekeler V; Neumann M; Frese G; Handgretinger R; Kardos G; Diddens H; Niethammer D Cancer Res; 1990 Nov; 50(21):6793-9. PubMed ID: 1698543 [TBL] [Abstract][Full Text] [Related]